Evidence map›Paper›PMID 41697989›Full record

ArticleJournal of the National Cancer Institute2026

Subsequent breast cancer risk after benign breast biopsy in racially diverse women: Siteman Cancer Center.

Alzina Koric, Debbie L Bennett, Fouad Boulos, Graham A Colditz

Abstract read
In one paragraph

Article in Journal of the National Cancer Institute, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Alzina KoricDivision of Public Health Sciences, Department of Surgery, Washington University School of Medicine, St. Louis, MO, United States.ORCID 0009-0003-9943-2945
Debbie L BennettAlvin J. Siteman Cancer Center, Barnes-Jewish Hospital and Washington University School of Medicine, St. Louis, MO, United States.ORCID 0000-0003-1898-0361
Fouad BoulosAlvin J. Siteman Cancer Center, Barnes-Jewish Hospital and Washington University School of Medicine, St. Louis, MO, United States.ORCID 0000-0003-1921-081X
Graham A ColditzDivision of Public Health Sciences, Department of Surgery, Washington University School of Medicine, St. Louis, MO, United States.ORCID 0000-0002-7307-0291

Funding

Washington University Center for Cellular ImagingP30CA091842 · NCI · WASHINGTON UNIVERSITY · PI TIMOTHY J. EBERLEIN · 2001 to 2026
$128.0M
Postdoctoral Training in Cancer Prevention and ControlT32CA190194 · NCI · WASHINGTON UNIVERSITY · PI GRAHAM A. COLDITZ, AIMEE S JAMES · 2014 to 2026
$4.7M
Breast Cancer Research Foundation BCRF 24-028Foundation for Barnes-Jewish Hospital and by Siteman Cancer CenterNational Cancer Institute (NCI) Cancer Center P30CA091842NCI NIH HHS P30 CA091842NCI NIH HHS T32 CA190194NIH HHS T32CA190194
6 · The paper itself

Abstract

backgroundThe association between histological subtypes of benign breast disease and subsequent breast cancer risk in the postmammography era of increased benign breast disease detection requires continued study to inform the clinical management of high-risk women.

methodsWe identified a cohort of 8915 women diagnosed with histologically confirmed benign breast lesions between 2010 and 2023 from the Joanne Knight Breast Health Center in St. Louis. Risk of subsequent breast events after a benign breast biopsy was assessed with Cox regression to estimate hazard ratios (HRs) and 95% confidence intervals (95% CIs).

resultsWithin a median follow-up of 6.5 years, 363 women developed breast cancer. The cohort was 63.7% White, 32.4% Black, and 3.9% Asian race. Breast cancer risk increased across subtypes of benign breast disease, from proliferative disease without atypia to atypical hyperplasia, with atypical hyperplasia risk modified by time since biopsy and menopause. Compared with women with nonproliferative disease, age-adjusted risk for breast cancer was 1.69 for proliferative disease without atypia (HR = 1.69, 95% CI = 1.35 to 2.12) and 2.78 for atypical hyperplasia (HR = 2.78, 95% CI = 2.01 to 3.85; P < .0001 for trend). Risk estimates attenuated but remained similar in fully adjusted models. Risks associated with benign breast disease subtypes were similar for Black and White women, but Black women with atypical hyperplasia had greater risk of breast cancer since recent biopsy (≤4 years) and during the premenopausal period (P = .033 for heterogeneity).

conclusionBreast cancer risk increases with the degree of epithelial proliferation, highest in atypical hyperplasia, amplified by recent biopsy and premenopause, particularly in Black women, consistent with the excess risk seen after ductal carcinoma in situ in this group.

Indexed as

BreastBreast DiseasesBreast NeoplasmsAdultAgedAsianBiopsyBlack or African AmericanFemaleFollow-Up StudiesHumansHyperplasiaMiddle AgedMissouriRisk FactorsWhite

Identifiers

PMID41697989
PMCPMC13112857

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.